Nestlé, Valbiotis partners to develop & commercialize plant-derived active substance, TOTUM-63 to reduce risk of developing type 2 diabetes

Nestlé Health Science and Valbiotis, a research and development company committed to scientific innovation for preventing and combating metabolic diseases, have entered into a strategic partnership for the development and commercialization of an innovative and patented product to reduce the risk of developing type 2 diabetes. TOTUM-63 is a combination of 5 plant extracts specifically designed to reduce the risk of developing type 2 diabetes on prediabetic subjects.

Hans-Juergen Woerle, chief science & medical officer of Nestlé Health Science, said, “The research and development that Valbiotis is doing is very promising. We look forward to working together to realize the commercialization of TOTUM-63, an innovative approach to reducing the risk of type 2 diabetes.”

Sébastien Peltier, CEO of Valbiotis commented, “Nestlé Health Science is an ideal strategic partner for Valbiotis. Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders like diabetes will be instrumental to TOTUM-63’s worldwide commercialization success. We are excited about the opportunity that this deal brings to Valbiotis and to the many millions of people around the world at risk of becoming type 2 diabetics. This transformational deal arrives just five years after the creation of Valbiotis and is a recognition of the hard work, commitment and vision of our team.”

Under the terms of the agreement, Valbiotis grants Nestlé Health Science exclusive and global commercial rights to use TOTUM-63 in the prediabetes and type 2 diabetes market. The partnership will support Valbiotis’ work in a number of ways, including funding the latest clinical development phase until health claims are obtained by regulatory authorities in the United States and Europe.